Abstract:Recent evidence shows a close link between Parkinson’s disease (PD) and cardiac dysfunction with limited treatment options. Mitophagy plays a crucial role in the control of mitochondrial quantity, metabolic reprogramming and cell differentiation. Mutation of the mitophagy protein Parkin is directly associated with the onset of PD. Parkin-independent receptor-mediated mitophagy is also documented such as BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) and FUN14 domain containing 1 (FUNDC1) for receptor-mediated mitophagy. In this study we investigated cardiac function and mitophagy including FUNDC1 in PD patients and mouse models, and evaluated the therapeutic potential of a SGLT2 inhibitor empagliflozin. MPTP-induced PD model was established. PD patients and MPTP mice not only displayed pronounced motor defects, but also low plasma FUNDC1 levels, as well as cardiac ultrastructural and geometric anomalies (cardiac atrophy, interstitial fibrosis), functional anomalies (reduced E/A ratio, fractional shortening, ejection fraction, cardiomyocyte contraction) and mitochondrial injury (ultrastructural damage, UCP2, PGC1α, elevated mitochondrial Ca2+ uptake proteins MCU and VDAC1, and mitochondrial apoptotic protein calpain), dampened autophagy, FUNDC1 mitophagy and apoptosis. By Gene set enrichment analysis (GSEA), we found overtly altered glucose transmembrane transport in the midbrains of MPTP-treated mice. Intriguingly, administration of SGLT2 inhibitor empagliflozin (10 mg/kg, i.p., twice per week for 2 weeks) in MPTP-treated mice significantly ameliorated myocardial anomalies (with exception of VDAC1), but did not reconcile the motor defects or plasma FUNDC1. FUNDC1 global knockout (FUNDC1−/− mice) did not elicit any phenotype on cardiac geometry or function in the absence or presence of MPTP insult, but it nullified empagliflozin-caused cardioprotection against MPTP-induced cardiac anomalies including remodeling (atrophy and fibrosis), contractile dysfunction, Ca2+ homeostasis, mitochondrial (including MCU, mitochondrial Ca2+ overload, calpain, PARP1) and apoptotic anomalies. In neonatal and adult cardiomyocytes, treatment with PD neurotoxin preformed fibrils of α-synuclein (PFF) caused cytochrome c release and cardiomyocyte mechanical defects. These effects were mitigated by empagliflozin (10 μM) or MCU inhibitor Ru360 (10 μM). MCU activator kaempferol (10 μM) or calpain activator dibucaine (500 μM) nullified the empagliflozin-induced beneficial effects. These results suggest that empagliflozin protects against PD-induced cardiac anomalies, likely through FUNDC1-mediated regulation of mitochondrial integrity.

Heart Failure Having Little Effect on the Progression of Parkinson's Disease: Direct Evidence from Mouse Model

MPTP-Induced Impairment of Cardiovascular Function

Antihypertensive drugs may not delay the symptom progression of Parkinson's disease: A 2-year follow-up study

The Interplay Between Small Vessel Disease and Parkinson Disease Pathology: A Longitudinal Study

Prevalence of Parkinson Disease in Hospitalized Patients With Congestive Heart Failure

Association between Parkinson's disease and the risk of adverse cardiovascular events: a systematic review and meta-analysis

Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping.

Association Between Heart Rate Variability and Parkinson’s Disease: A Meta-analysis

Spatiotemporal Neurodegeneration of the Substantia Nigra and Its Connecting Cortex and Subcortex in Parkinson's Disease.

Cardiovascular outcomes in Parkinson's disease patients from a retrospective cohort study

Increases In The Risk Of Cognitive Impairment And Alterations Of Cerebral Beta-Amyloid Metabolism In Mouse Model Of Heart Failure

Mitochondrial Dysfunction as a Potential Mechanism Mediating Cardiac Comorbidities in Parkinson's Disease

Estimating motor progression trajectory pursuant to temporal dynamic status of cardiac denervation in Parkinson's disease

The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease

Induction of periodontitis and oral microbiome dysbiosis in a mouse model with heart failure with preserved ejection fraction results in worsening hypertension and diastolic dysfunction

SGLT2 Inhibitor Empagliflozin Alleviates Cardiac Remodeling and Contractile Anomalies in a FUNDC1-dependent Manner in Experimental Parkinson’s Disease

The association between age-related macular degeneration and risk of Parkinson disease: A systematic review and meta-analysis

Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease

Progressive brain changes in Parkinson’s disease: A meta-analysis of structural magnetic resonance imaging studies

Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease

White matter hyperintensities and the progression from mild parkinsonian signs to parkinsonism and Parkinson’s disease